Index to Volume 7

Author Index

— A —

Adelman MH: *see* Schentag JJ, et al, 80
Angaran D: Pharmacologic and pharmacokinetic comparison of anti anginal agents, 62S
Arjan Singh B: Original photo (Bengal tiger, India), 164

— B —

Baden HP: *see* Kvedar JC, et al, 191
Bagby GF: *see* O'Brien WM, 16
Bailey FL: Legal factors surrounding drug testing in the workplace, 58
Bauman JL: *see* Berry NS, et al, 210
Bauman JL: *see* Berk SI et al, 145
Benotti PN: *see* Shea BF, 54
Berk SI, Bauman JL: Commentary on enalapril, 145
Berry NS, Bauman JL: Commentary on lovastatin, 210
Binkley PF: *see* Leier CV, et al, 61
Blend MJ: *see* Zeller FP, et al, 178
Borek M, Charlap S, Frishman W: Enalapril: a long-acting angiotensin-converting enzyme inhibitor, 133
Bowden CL: *see* Sommi RW, et al, 1
Bryant SG, Fisher S, Kluge RM: Increased frequency of doxycycline side effects, 125

— C —

Canafax DM, Draxler CA: Monoclonal antilymphocyte antibody (OKT3) treatment of acute allograft rejection, 121
Canafax DM: *see* Chan GLC, et al, 165
Chan GLC, Canafax DM, Johnson CA: The therapeutic use of azathioprine in renal transplantation, 165
Chandrasekar PH: *see* Pilla AM, et al, 188
Charlap S: *see* Borek M, et al, 133
Clements SD: *see* Rogers SD, et al, 111
Cox SR, Forbes KK: Excretion of flurbiprofen into breast milk, 211
Cramer WR: Original photo (Lemur macaco, Madagascar), 86
Crismon ML: *see* Sommi RW, et al, 1

— D —

da Camara CC, Weiner B, Stetz JJ: Acute bacterial endocarditis due to Hemophilus parainfluenzae. Response to ceftizoxime in an ampicillin-allergic patient, 185
Draxler CA: *see* Canafax DM, et al, 121
Drayer DE: Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers, 87
Dudley MN: Commentary on norfloxacin, 107

— E —

Estes NAM: *see* Tordjman T, et al, 149

— F —

Faich GA: Risks and indications of phenylbutazone: another look, 25
Faulkner HC; *see* Gammans RE, et al, 72
Fiedler VB: *see* Nitz RE, et al, 28
Fisher S: *see* Bryant SG, et al, 125
Forbes KK : *see* Cox SR, et al, 211
Frishman W: *see* Borek M, et al, 133

— G —

Gammans RE, Pfeffer M, Westrick ML, Faulkner HC, Rehm KD, Goodson PJ: Lack of interaction between cimetidine and buspirone, 72
Gelenberg AJ: Commentary on fluoxetine, 14
Gerbino PP: Preface to histamine antagonists supplement, 89S
Gleckman RA: Commentary on norfloxacin, 107
Goodson PJ: *see* Gammans RE, et al, 72
Grasela TH: *see* Schentag JJ, et al, 80

— H —

Haffajee CI: Commentary on encainide, 158
Hammer SM, *see* Shea BF, et al, 223
Hammer SM: *see* Shea BF, 54
Harbison MA: *see* Shea BF, 54
Hoffman S: *see* Shea BF, et al, 223

— J —

Johnson CA: *see* Chan GLC, et al, 165

— K —

Kluge RM: *see* Bryant SG, et al, 125
Knodell RG, Rosenthal LE: Stress-related mucosal damage: critical evaluation of potential new therapeutic agents, 104S
Knox EP: *see* Laird LK, et al, 130
Krukemyer JJ, Talbert RL: Lovastatin: a new cholesterol-lowering agent, 198
Kvedar JC, Baden HP: Topical minoxidil in the treatment of male pattern alopecia, 191

— L —

Labreche DG: Commentary on encainide, 160
Laird LK, Knox EP: The use of carbamazepine and lithium in controlling a case of chronic rapid cycling, 130
LeBel M, Pugsley J: Commentary on norfloxacin, 109
Leier CV, Majetich N Jr, Binkley PF, Unverferth DV: Hemodynamic responses to indoramin at rest and during exercise in congestive heart failure, 61

Letendre PW: Preface to the symposium on silent myocardial ischemia, 55S
Levine BA: Pathophysiology and mechanisms of stress ulcer injury, 90S

— M —

Majetich N Jr: *see* Leier CV, et al, 61
Manolis AS, Varriale P, Nobile J: Short-term hemodynamic effects of intravenous methyldopa in patients with congestive heart failure, 216
Marshall LE: *see* Thomas, et al, 47
Mavligit GM: Immunologic effects of cimetidine: potential uses, 120S
Michel DJ: *see* Rowen RC, et al, 92
Morris JJ Jr: Silent myocardial ischemia: pathophysiology and clinical recognition, 56S
Musa DM, Pauly DJ: Evaluation of a new vancomycin dosing method, 69

— N —

Naccarelli GV: Commentary on encainide, 159
Nitz RE, Fiedler VB: Molsidomine: alternative approaches to treat myocardial ischemia, 28
Nobile J: *see* Manolis AS, et al, 216

— O —

O'Brien WM, Bagby GF: Carprofen: a new nonsteroidal antiinflammatory drug, 16

— P —

Parker WA, Sketris IS: Commentary on carprofen, 24
Pauly DJ: *see* Musa DM, et al, 69
Peura DA: Recognizing, setting therapeutic goals, and selecting therapy for the prevention and treatment of stress-related mucosal damage, 95S
Pfeffer M: *see* Gammans RE, et al, 72
Pilla AM, Rybak MJ, Chandrasekar PH: Spiramycin in the treatment of cryptosporidiosis, 188
Pugsley J: *see* LeBel M, et al, 109

— R —

Rehm KD: *see* Gammans RE, et al, 72
Riemersma LB: *see* Rogers SD, et al, 111
Rogers SD, Riemersma LB, Clements SD: Tissue plasminogen activator: An evaluation of clinical efficacy in acute myocardial infarction, 111
Rosenthal LE: *see* Knodell RG, et al, 104S
Rowen RC, Michel DJ, Thompson JC: Norfloxacin: clinical pharmacology and clinical use, 92
Rybak MJ: *see* Pilla AM, et al, 188

— S —

Sabesin SM, Weidman SW: Histamine H2 receptor antagonists and high-density lipoproteins, 116S
Sax MJ: Clinically important adverse effects and drug interactions with H2 receptor antagonists, 110S
Scheife RT: Original photo (Hilly people, Nepal), 56
Scheife RT: Editorial: Drug testing in the workplace — Pivotal perspectives, 57
Scheife RT: Original photo (Mombasa, Kenya), 110
Schentag JJ, Welage LS, Grasela TH, Adelman MH: Determinants of antibiotic-associated hypoprothrombinemia, 80
Sesin GP, *see* Shea BF, et al, 223
Sesin GP: *see* Shea BF, et al, 54
Shea BF, Harbison MA, Sesin GP, Benotti PN, Hammer SM: Acyclovir-associated fever: a case report, 54
Shea BF, Hoffman S, Sesin GP, Hammer SM: Ganciclovir hepatotoxicity, 223
Sketris IS: *see* Parker WA, et al, 24
Sommi RW, Crismon ML, Bowden CL: Fluoxetine: a serotonin-specific, second-generation antidepressant, 1
Speeg KV: Potential uses of cimetidine for treatment of acetaminophen overdose, 125S
Stein GE: Commentary on norfloxacin, 106
Stetz JJ: *see* da Camara CC, et al, 185
Stimmel GL: Commentary on fluoxetine, 14

— T —

Talbert RL: *see* Krukemyer JJ, et al, 198
Thomas RL, Watson D, Marshall LE: Review of intermittent dobutamine infusions for congestive cardiomyopathy, 47
Thompson JC: *see* Rowen RC, et al, 92
Tonkon M: Hemodynamic profiles of antianginal agents, 72S
Tordjman T, Estes NAM: Encainide: its electrophysiologic and antiarrhythmic effects, pharmacokinetics, and safety, 149
Touchon R: Clinical management of asymptomatic myocardial ischemia, 76S

— U —

Unverferth DV: *see* Leier CV, et al, 61

— V —

Varriale P: *see* Manolis AS, et al, 216

— W —

Watson D: *see* Thomas, et al, 47
Weidman SW: *see* Sabesin SM, et al, 116S
Weinberger M: Commentary on enalapril, 146
Weiner B: Commentary on lovastatin, 209
Weiner B: *see* da Camara CC, et al, 185
Welage LS: *see* Schentag JJ, et al, 80
Westrick ML: *see* Gammans RE, et al, 72

— Z —

Zeller FP, Blend MJ: The use of intravenous dipyridamole in thallium 201 myocardial perfusion imaging, 178

— A —

Acetaminophen overdose, potential use of cimetidine in, 125S
Acute myocardial infarction, evaluation of tissue plasminogen activator in, 111
Acyclovir, fever caused by, 54
Alopecia, male pattern, topical minoxidil in the treatment of, 191
Antianginal agents, pharmacologic and pharmacokinetic comparison of, 62S
Antianginal agents, hemodynamic profiles of, 73S
Antibiotic-associated hypoprothrombinemia, determinants of, 80
Antibody immunotherapy, of gram-negative sepsis, 31S
Asymptomatic myocardial ischemia, clinical management of, 76S
Autoimmune neutropenia, immunotherapy of, 41S
Azathioprine, therapeutic use in renal transplantation, 165

— B —

Bacterial endocarditis, acute due to H. parainfluenzae, response to ceftizoxime, 185
Beta blockers, lipophilicity, hydrophilicity, and the CNS effects of, 87
Bone marrow, transplantation of, 23S
Breast milk, excretion of flurbiprofen into, 211
Buspirone, lack of interaction between cimetidine and, 72

— C —

Carbamazepine and lithium, in controlling a case of chronic rapid cycling, 130
Carprofen, chemistry, 16; animal studies, 17; human pharmacology, 18; clinical trials, 19; adverse reactions, 21
Ceftizoxime, acute bacterial endocarditis due to H. parainfluenzae, response to, 185
Central nervous system side effects, beta blockers, lipophilicity, hydrophilicity and, 87
Cimetidine, immunologic effects of, 120S
Cimetidine, potential use in acetaminophen overdose, 125S
Cimetidine, lack of interaction between buspirone and, 72
Congestive cardiomyopathy, use of intermittent dobutamine infusions in, 47
Cryptosporidiosis, spiramycin in the treatment of, 188

— D —

Dipyridamole, intravenous, use in thallium 201 myocardial perfusion imaging, 178
Dobutamine, intermittent infusions for congestive cardiomyopathy, 47
Doxycycline, increased frequency of side effects of, 125
Drug testing, editorial, 57
Drug testing, legal factors surrounding, 58

— E —

Enalapril, structure and pharmacokinetics, 133; humoral effects, 135; hemodynamic effects, 136; renal effects, 138; fluid and electrolyte balance, 139; clinical experience, 140; adverse reactions, 141
Encainide, basic electrophysiology, 149; electrocardiographic effects, ventricular arrhythmias, 150; supraventricular arrhythmias, 152; adverse effects, 153; pharmacokinetics, 154; hemodynamic effects, drug interactions, 156
Endocarditis, acute bacterial, due to H. parainfluenzae, response to ceftizoxime, 185

— F —

Fever, caused by acyclovir, 54
Fluoxetine, history, 1; toxicology, 11; formulary considerations, 12; mechanism of action, 2; pharmacokinetics, 4; indications, 7; adverse reactions, 8
Flurbiprofen, excretion into breast milk, 211

— G —

Ganciclovir, hepatotoxicity of, 223
Gram-negative sepsis, antibody immunotherapy of, 31S

— H —

H2 histamine antagonists, adverse effects and drug interactions, 110S
H2 histamine antagonists, high-density lipoproteins and, 116S
HLA, role of in disease, 7S
Hepatotoxicity, of ganciclovir, 223
High-density lipoproteins, H2 histamine receptor antagonists and, 116S
Hydrophilicity, and the CNS effects of beta blockers, 87
Hypercholesterolemia, use of lovastatin in, 198
Hypoprothrombinemia, antibiotic-associated, determinants of, 80

— I —

Idiopathic thrombocytopenic purpura, immunotherapy of, 41S
Immunologic effects of, cimetidine, 120S
Immunology, basics tenets of, 3S
Immunotherapy, indications for, 12S
Immunotherapy, of ITP and autoimmune neutropenia, 41S
Indoramin, hemodynamic response to in congestive heart failure, 61
Intravenous immune globulin, dosage and administration, 27S
Intravenous immunoglobulin, safety and production of, 26S

— L —

Lipophilicity, and the CNS effects of beta blockers, 87
Lithium and carbamazepine, in controlling a case of chronic rapid cycling, 130
Lovastatin, use in hypercholesterolemia, 198

— M —

Methyldopa, short-term hemodynamic effects in patients with congestive heart failure, 216
Minoxidil, in the treatment of male pattern alopecia, 191
Molsidomine, use in treatment of myocardial ischemia, 28
Monoclonal antilymphocyte antibody (OKT3), in treatment of acute renal allograft rejection, 121
Myocardial imaging, thallium 201, use of intravenous dipyridamole in, 178
Myocardial ischemia, use of molsidomine in, 28
Myocardial ischemia, asymptomatic, clinical management of, 76S

— N —

Norfloxacin, adverse reactions, 103; dosage and administration, 103; place in therapy, 104; history, 92; chemistry, mechanism of action, bacterial resistance, 93; spectrum of activity, 94; pharmacokinetics, 96; clinical trials, 98

— O —

OKT3 (monoclonal antilymphocyte antibody), in treatment of acute renal allograft rejection, 121
Organ transplantation, recent advances in 20S

— P —

Phenylbutazone, risks and indications, 25

— R —

Rapid cycling, chronic, use of carbamazepine and lithium in controlling, 130
Renal transplantation, use of azathioprine in, 165

— S —

Silent myocardial ischemia, pathophysiology and clinical recognition, 56S
Spiramycin, in the treatment of cryptosporidiosis, 188
Stress ulcer injury, pathophysiology and mechanisms of, 90S
Stress-related mucosal damage, evaluation of new therapeutic agents in, 104S
Stress-related mucosal damage, therapy and prevention of, 95S

— T —

TPA, see tissue plasminogen activator, 111
Thallium 201 myocardial imaging, use of intravenous dipyridamole in, 178
Tissue plasminogen activator, evaluation of clinical efficacy in acute myocardial infarction, 111
Transplantation, recent advances in, 20S

— V —

Vancomycin, evaluation of a new dosing method for, 69


1.0
1.1
1.25
1.4
1.6
1.8
2.0
2.2
2.5
2.8
3.2
3.6
4.0
4.5
5.0
5.6
6.3
7.1
8.0
9.0
10.0